Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
Ronald ChowLeonard ChiuJørn HerrstedtMatti AaproMichael LockCarlo DeAngelisRudolph M NavariPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
Olanzapine-containing regimens are both cheaper and more effective in the prophylaxis of CINV in HEC patients, compared with non-olanzapine-containing regimens. Future CINV trial resources should be allocated to understand newer antiemetics and compare them to olanzapine-containing regimens as the control arm. Further analysis should use nationally representative data to examine medication costs by payer type.
Keyphrases
- chemotherapy induced
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- clinical trial
- emergency department
- squamous cell carcinoma
- electronic health record
- machine learning
- open label
- phase iii
- artificial intelligence
- current status
- adverse drug
- drug induced